We conclude that I-DOX represents an important treatment option for subjects with AL amyloidosis and could be the prototype of a new class of drugs that interfere with and reverse the process of all types of amyloid deposition.doi:10.1182/blood.V86.3.855.bloodjournal8638...
3 Progression of AL amyloidosis from precursor plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) can occur and hematologists must carefully monitor these patients for signs or symptoms concerning AL amyloidosis.4 Navigating the A...
New Indications & Dosage Forms for Existing DrugsDrugs that have gained FDA approval for the treatment of additional diseases/conditions or new dosage forms/regimens.Nemluvio (nemolizumab) for Injection New Indication Approved: December 13, 2024 Date of Original Approval: August 12, 2024 Nemluv...
- 《Clinical Cancer Research An Official Journal of the American Association for Cancer Research》 被引量: 164发表: 2008年 Managing Systemic Light-Chain Amyloidosis Drugs effective in multiple myeloma are usually active in AL, depending on side effects. New agents such as bortezomib and lenalidomide...
Ixazomib is a novel oral proteasome inhibitor which is being studied in multiple myeloma and systemic light-chain (AL) amyloidosis, and other malignancies. Ixazomib was granted orphan drug designation for the treatment of patients with relapsed or refractory multiple myeloma by the Ministry of Health...
The Aβ hypothesis is the mainstream hypothesis for the pathogenesis of AD and has influenced the direction of drug development over the past three decades. According to the hypothesis, the pathological progression of AD originates from asymptomatic cerebral amyloidosis many years before the onset of...
Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27:18. CAS PubMed PubMed Central Google Scholar Suidan GL, Ramaswamy G. Targeting apolipoprotein E for Alzheimer’s disease: an industry perspective. Int J Mol Sci. 2019;20:2161. https://doi.org/10.3390/ijms20092161...
amyloidosis (hATTR).294,295,296Indeed, the rapid development of siRNA is benefit from lipid nanoparticles (LNPs) technology progress and related nucleic acid modification methods.297,298,299Researchers also use siRNAs for the treatment of autoimmune diseases and achieved some progress.300,301...
Interestingly, a subset of FDA-approved drugs such as the muscle relaxant lanperisone and the analgesic acetaminophen (N-acetyl-p-aminophenol, or APAP) have been shown to activate ferroptosis by functionally suppressing system Xc–. For example, lanperisone has been shown to effectively targetRAS...
[1]. This lipid nanoparticle (LNP)-encapsulated small interfering RNA (siRNA) was approved by the United States Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis, marking a significant milestone in the field and opening the door for mRNA-based drugs to be used...